Syndax, Royalty Pharma enter into $350M royalty funding deal

poba Syndax Pharmaceuticals ( NASDAQ: SNDX ) and Royalty Pharma ( NASDAQ: RPRX ) have entered into a $350M synthetic royalty funding agreement for net sales of Syndax’s ( SNDX ) Niktimvo. Under the deal, Syndax ( SNDX ) will receive an upfront payment of $350M in exchange for a 13.8% royalty.